Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

The binding between a biosimilar and ... across the life span of the products. Stability of Her2 under 37 ℃ was determined by SDS-PAGE and ELISA Human Her2, His Tag (Cat. No. HE2-H822R ) on ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor.

The membrane-associated glycoprotein mucin-4 (MUC4) could block inhibitory actions of trastuzumab by directly binding with HER2, preventing interaction between the drug and its molecular target.

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.

In the almost 30-years since the protests at the Genentech headquarters, HER2+ breast cancer treatments that include Herceptin® - such as chemotherapy with the addition of Herceptin® or ...

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

HER2-low breast cancer falls somewhere in between. Thanks to new targeted treatments, such as a drug called trastuzumab deruxtecan, patients with HER2-low breast cancer now have more options and ...